Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2022

View Archived Issues

FVIII-QQ gene transfer therapy shows advantage for treating hemophilia A

Novel genetic polymorphism associated with macroangiopathy risk

UCB SA patents DRD1 PAMs

Merck & Co. discloses new DNA polymerase inhibitors

Pfizer synthesizes IL-2 production inhibitors

Janssen Pharmaceutica identifies new Mcl-1 inhibitors

GLS1 inhibitor with antitumor activity in HCT116 xenograft model

Heptares Therapeutics divulges new histamine H4 receptor antagonists

Inflammation, coagulation and endothelial activation markers linked to HIV-associated TTP

A new series of broad-spectrum bacterial type II topoisomerase inhibitors: synthesis and evaluation

New salicylic acid derivatives act as double GO/LACH inhibitors to decrease oxalate production

SNP rs11549465 in HIF1A gene predicts glucocorticoid sensitivity in patients with ITP

FDA awards orphan drug designation to AVR-RD-05 for Hunter's syndrome

CytomX restructures and outlines plans for preclinical pipeline

KDM4B enzyme inhibitor tested for aggressive rhabdomyosarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...